Methods and kits for detection of thromboxane A2 metabolites
View Patent ↗Methods, compositions and kits are provided for measuring aspirin's anti-thrombotic effectiveness on a subject. Included are a novel assay for quickly and specifically measuring TxA2 metabolite levels in urine and correlating the levels with aspirin dose in a subject. The methods, compositions and kits utilize a novel anti TxA2 metabolite antibody.
1. A composition comprising a monoclonal antibody, wherein the antibody recognizes 11-dehydro Thromboxane B 2 and 11-dehydro-2,3,-dinor Thromboxane B 2 .
2. The composition of claim 1 , wherein the monoclonal antibody recognizes the 11-dehydro Thromboxane B 2 metabolite and 11-dehydro-2,3-dinor Thromboxane B 2 metabolite with similar binding ratios, the ratio of 11-dehydro Thromboxane B 2 :11-dehydro-2,3-dinor Thromboxane B 2 is from 0.5:1 to 1:0.5.
3. The composition of claim 2 , wherein the ratio of 11-dehydro Thromboxane B2:11-dehydro-2,3-dinor Thromboxane B 2 is from 0.6:1 to 1:0.6.
4. The composition of claim 1 , wherein the monoclonal antibody recognizes an epitope common to both 11-dehydro Thromboxane B 2 and 11-dehydro-2,3-dinor Thromboxane B 2 .
5. The composition of claim 1 , wherein the monoclonal antibody recognizes an epitope having the following formula:
6. The composition of claim 1 , wherein the monoclonal antibody is less than 2% reactive with one or more of 2,3 dinor TxB2, PGD2, TxB2, 6-keto PGF1a, PGE2, PGEM, and PGFM.
7. The composition of claim 1 , wherein the monoclonal antibody is less than 2% reactive with each of 2,3 dinor TxB2, PGD2, TxB2, 6-keto PGF1a, PGE2, PGEM, and PGFM.
8. A monoclonal antibody which recognizes two thromboxane A 2 metabolites, wherein the two thromboxane A 2 metabolites are 11-dehydro Thromboxane B 2 and 11-dehydro-2,3,-dinor Thromboxane B 2 .
9. The monoclonal antibody of claim 8 , wherein the monoclonal antibody recognizes an epitope having the following formula:
10. The monoclonal antibody of claim 8 , wherein the monoclonal antibody is less than 2% reactive with one or more of 2,3 dinor TxB2, PGD2, TxB2, 6-keto PGF1a, PGE2, PGEM, and PGFM.
11. The monoclonal antibody of claim 8 , wherein the monoclonal antibody is less than 2% reactive with each of 2,3 dinor TxB2, PGD2, TxB2, 6-keto PGF1a, PGE2, PGEM, and PGFM.
12. The monoclonal antibody of claim 8 , wherein the antibody shows at least 50% cross-reactivity with 11 dh TxB2 and 11-dehydro-2,3 dinor thromboxane B2.